Fig. 1
![Fig. 1](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40169-019-0246-5/MediaObjects/40169_2019_246_Fig1_HTML.png)
Prognostic analyses of CYP19A1–ESR axis in breast cancer. a–d OS, RFS, DMFS and PPS of integrated CYP19A1 and ESR1/ESR2 in breast cancer patients (n = 1402 in OS, 3951 in RFS, 1746 in DMFS, 414 in PPS respectively). e–h OS, RFS, DMFS and PPS of integrated CYP19A1 and ESR1/ESR2 in untreated breast cancer patients (n = 382 in OS, 1010 in RFS, 543 in DMFS, 137 in PPS respectively). The detailed HR and logrank p-value were individually shown as indicated in each panel, and p-value < 0.05 was considered statistically significant